Abstract:N6-methyladenosine (m6A) is the most abundant epigenetic modification of RNA, and its dysregulation drives aberrant transcription and translation programs that promote cancer occurrence and progression. Although defective gene regulation resulting from m6A often affects oncogenic and tumor-suppressing networks, m6A can also modulate tumor immunogenicity and immune cells involved in anti-tumor responses. Understanding this counterintuitive concept can aid the design of new drugs that target m6A to potentially improve the outcomes of cancer immunotherapies. Here, we provide an up-to-date and comprehensive overview of how m6A modifications intrinsically affect immune cells and how alterations in tumor cell m6A modifications extrinsically affect immune cell responses in the tumor microenvironment (TME). We also review strategies for modulating endogenous anti-tumor immunity and discuss the challenge of reshaping the TME. Strategies include: combining specific and efficient inhibitors against m6A regulators with immune checkpoint blockers; generating an effective programmable m6A gene-editing system that enables efficient manipulation of individual m6A sites; establishing an effective m6A modification system to enhance anti-tumor immune responses in T cells or natural killer cells; and using nanoparticles that specifically target tumor-associated macrophages (TAMs) to deliver messenger RNA or small interfering RNA of m6A-related molecules that repolarize TAMs, enabling them to remodel the TME. The goal of this review is to help the field understand how m6A modifications intrinsically and extrinsically shape immune responses in the TME so that better cancer immunotherapy can be designed and developed.

Roles and therapeutic implications of m6A modification in cancer immunotherapy

The Regulation of N6‐methyladenosine Modification in PD‐L1‐induced Anti‐tumor Immunity

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Role of m6A modifications in immune evasion and immunotherapy

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

Targeting the RNA M6a Modification for Cancer Immunotherapy

The Role of m6A Methylation in Tumor Immunity and Immune-Associated Disorder

Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification

N6-methyladenosine (m6a) RNA Modification in Tumor Immunity

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors

Targeting N6-methyladenosine RNA Modification Combined with Immune Checkpoint Inhibitors: A New Approach for Cancer Therapy

Targeting RNA N6-methyladenosine to Synergize with Immune Checkpoint Therapy

Dual Effects of N6-methyladenosine on Cancer Progression and Immunotherapy

The Roles of M6a RNA Modifiers in Human Cancer

The role of m6A-mediated PD-1/PD-L1 in antitumor immunity

The Importance of N6-methyladenosine Modification in Tumor Immunity and Immunotherapy.

The roles and mechanism of m6A RNA methylation regulators in cancer immunity

Role of N6-methyladenosine RNA modification in cancer

Emerging roles of m6A RNA modification in cancer therapeutic resistance

A new perspective on hematological malignancies: m6A modification in immune microenvironment

Epigenetic modification of m6A regulator proteins in cancer